B

BridgeBio Pharma
D

BBIO

23.430
USD
0.17
(0.73%)
مغلق
حجم التداول
75,345
الربح لكل سهم
-3
العائد الربحي
-
P/E
-10
حجم السوق
4,428,031,061
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AACG
    -0.03000
    (-2.94%)
    0.99000 USD
    ABBV
    ABBV
    -4.630
    (-2.73%)
    176.95 USD
    A
    ABCL
    -0.11000
    (-3.99%)
    2.65000 USD
    ABEV
    ABEV
    0.01000
    (0.45%)
    2.21000 USD
    A
    ACOR
    -0.26810
    (-30.48%)
    0.61160 USD
    A
    ALB
    1.450
    (1.42%)
    103.570 USD
    A
    ALLO
    -0.19000
    (-7.71%)
    2.27500 USD
    A
    ALT
    -0.85500
    (-10.11%)
    7.60000 USD
    A
    AMRN
    -0.01500
    (-2.88%)
    0.50510 USD
    A
    AMRX
    -0.53500
    (-5.94%)
    8.47500 USD
    A
    ANAB
    -1.150
    (-5.69%)
    19.060 USD
    A
    ASB
    -0.090
    (-0.34%)
    26.590 USD
    A
    AXDX
    -0.01000
    (-0.54%)
    1.85000 USD
    A
    AXSM
    -4.300
    (-4.41%)
    93.150 USD
    B
    BCRX
    -0.41500
    (-5.57%)
    7.03500 USD
    المزيد
الأخبار

العنوان: BridgeBio Pharma

القطاع: Healthcare
الصناعة: Biotechnology
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, acoramidis (AG10), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.